Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services.
about
Drug use among complete responders, partial responders and non-responders in a longitudinal survey of nonagenarians: analysis of prescription register data.Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study.The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD).A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practiceAdverse drug reactions in special populations - the elderly.Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analysesPrevalence of, and Resident and Facility Characteristics Associated With Antipsychotic Use in Assisted Living vs. Long-Term Care Facilities: A Cross-Sectional Analysis from Alberta, Canada.Inequalities in receipt of mental and physical healthcare in people with dementia in the UK.Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice.Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial.Modeling and evaluating evidence-based continuing education program in nursing home dementia care (MEDCED)--training of care home staff to reduce use of restraint in care home residents with dementia. A cluster randomized controlled trial.Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors.Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia: protocol for a systematic review and network meta-analysis.Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.Antipsychotic Use in Dementia.Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany.Quality of care for people with dementia and professional caregivers' perspectives regarding palliative care in Japanese community care settings.Change in psychotropic drug use in Norwegian nursing homes between 2004 and 2011.Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review.Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort studyDevelopment of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus studyNurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines
P2860
Q31139638-D3164A9B-AD01-474C-B275-D9670E871BEDQ33604532-6FA451B0-FA6B-4451-8732-7E8FF0365FC9Q33736204-A07A29B8-64C1-408B-BA25-9C4EA012C6DFQ35848943-6F0DAE49-6735-42B4-A8C7-CF0E7E04AD1FQ36091476-028F47D0-679B-4FD1-8007-C4FE1196D20DQ36125513-6D826171-6249-4242-B90C-FB9A633421F1Q37196381-7A50625C-8229-4DFB-A856-B46848B47943Q37575077-E5E60EDD-58DA-467A-B596-6AB94803040CQ37735666-14B2605A-AA4B-4FC1-BB70-482CF815AC06Q38214498-9B2250CE-2703-4413-A37B-EFDC8D210513Q38691294-4A6E3DA6-6FC1-47E6-AF88-4D122EC0B85CQ38957896-3F9F0095-39CB-4AF2-A9C3-91957A4F83EEQ39021319-D703826A-5C5D-4F75-9653-9BCD0752C9E4Q39051107-E22D4BAC-EB41-4BDA-BC3A-EAEAB8F29075Q40052919-8BCB7654-90D7-4ACB-B466-038BB31160B6Q41682303-61E7AEA3-558D-4D4F-89EE-47FD4B2CB4ABQ41827089-6E782925-D189-47AA-9450-1077F378DA18Q47680282-3F8B43E4-8A42-4C87-BE52-EB5CB7529B4BQ47875379-B03CD858-1953-4485-90CD-21E2B67E0374Q49499746-ECE58C69-4DB8-4A83-9716-844331A7EECEQ55000556-0FD0C087-2046-4864-A0C3-45088AAFD226Q57916505-A9F0973A-EBCC-4738-84C3-79CC6CFA9C7DQ58694588-E0067FAE-A998-4B37-B8FB-235DBD53250FQ59125704-D69CCDD8-7730-4E46-9731-A8809EB1DA82
P2860
Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antipsychotics in dementia: pr ...... in UK mental health services.
@en
type
label
Antipsychotics in dementia: pr ...... in UK mental health services.
@en
prefLabel
Antipsychotics in dementia: pr ...... in UK mental health services.
@en
P2093
P1476
Antipsychotics in dementia: pr ...... in UK mental health services.
@en
P2093
Adrian Treloar
Carol Paton
Noel Collins
Samantha M McIntyre
Sube Banerjee
Thomas R E Barnes
P304
P356
10.1192/BJP.BP.111.107631
P407
P577
2012-07-12T00:00:00Z